Singapore: Pharmaceutical company, Mundipharma, has derived positive results from its Betadine formulations, used for skin disinfection and surgical skin preparations, in controlling the Ebola virus.

The testing was conducted at Marburg University, Germany.The Betadine range includes products such antiseptic solution, surgical scrub, alcoholic antiseptic solution for skin disinfection and hand hygiene in hospitals and healthcare institutions.

The tested betadine formulations showed an virucidal efficacy against the Ebola virus demonstrating its potential in fighting the outbreak and in minimising the risk of human to human transmission.

Mr Raman Singh, president, Asia Pacific, Latin America, Middle East, and Africa, Mundipharma commented: "The Ebola virus, amongst others, is a very real threat to many of the populations of the regions in which we work. Mundipharma is proud to be able to support efforts to curb these epidemics, demonstrating the breadth and efficacy of our products and helping to inform and educate those at risk."

"The excellent results from our study with Betadine confirm its potential in the prevention and limiting the spread of Ebola. We are hopeful that these results from our research will bring great value to the medical community and society in the management of Ebola crisis. The race to stay ahead of viral epidemics is constant," said Prof Dr Maren Eggers, the virologist who led the investigations.